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PD-1 on Immature and PD-1 Ligands on Migratory
Human Langerhans Cells Regulate Antigen-Presenting
Cell Activity
Victor Pen˜a-Cruz1, Sean M. McDonough1,4, Felipe Diaz-Griffero2,4, Christopher P. Crum3,
Ruben D. Carrasco1 and Gordon J. Freeman1
Langerhans cells (LCs) are known as ‘‘sentinels’’ of the immune system that function as professional antigen-
presenting cells (APCs) after migration to draining lymph node. LCs are proposed to have a role in tolerance and
the resolution of cutaneous immune responses. The Programmed Death-1 (PD-1) receptor and its ligands, PD-L1
and PD-L2, are a co-inhibitory pathway that contributes to the negative regulation of T-lymphocyte activation
and peripheral tolerance. Surprisingly, we found PD-1 to be expressed on immature LCs (iLCs) in situ. PD-1
engagement on iLCs reduced IL-6 and macrophage inflammatory protein (MIP)-1a cytokine production in
response to TLR2 signals but had no effect on LC maturation. PD-L1 and PD-L2 were expressed at very low levels
on iLCs. Maturation of LCs upon migration from epidermis led to loss of PD-l expression and gain of high
expression of PD-L1 and PD-L2 as well as co-stimulatory molecules. Blockade of PD-L1 and/or PD-L2 on
migratory LCs (mLCs) and DDCs enhanced T-cell activation, as has been reported for other APCs. Thus the PD-1
pathway is active in iLCs and inhibits iLC activities, but expression of receptor and ligands reverses upon
maturation and PD-L1 and PD-L2 on mLC function to inhibit T-cell responses.
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INTRODUCTION
Langerhans cells (LCs) are myeloid-derived dendritic cells
(DCs) distributed along the stratified epithelia of tissues
exposed to the environment such as skin and mucosa. LCs are
known as ‘‘sentinels’’ of the immune system and form a
network in the epidermis where they actively take up antigen
by extending and retracting their dendrites. During migration
to draining lymph nodes, LCs process antigen and upregulate
the level of co-stimulatory molecules. In the lymph node, LCs
function as professional antigen-presenting cells (APCs)
(Merad et al., 2008). In the steady state, LCs are proposed
to have a role in tolerance and the resolution of cutaneous
immune responses.
Although DCs can function as inducers of T-cell
activation, they also have a role in peripheral tolerance
(Banchereau and Steinman, 1998; Steinman et al., 2003). In
murine models when DCs present antigen in the absence of
inflammation and pathogenic stimulus, they can induce
peripheral tolerance (Hawiger et al., 2001; Bonifaz et al.,
2002). There is increasing evidence for a role of LCs in
tolerance (Merad et al., 2008); however, most of these studies
have been conducted using mouse models and the results are
controversial. For instance, it has been suggested that
epidermal LCs induce tolerance through stimulation of
regulatory T cell development (Loser et al., 2006). However,
Langerinþ cells that have migrated to the lymph node
express high levels of CD80, CD86, CD40, and major
histocompatibility complex class-II, as well as PD-1 ligand
(PD-L)1 and PD-L2, suggesting that the function of these LCs
in mice is not tolerogenic (Stoitzner et al., 2005).
Here we explore the expression and function of a
co-inhibitory pathway, PD-1 and PD-1 ligands, on LCs. PD-1
(CD279) is a CD28 family member expressed on activated T
and B cells, as well as some myeloid cells (Okazaki and
Honjo, 2007). PD-1 delivers a co-inhibitory signal upon
binding to either of its two ligands PD-L1 (B7-H1; CD274) or
PD-L2 (B7-DC; CD273) (Greenwald et al., 2005). The PD-1
pathway has a role in peripheral tolerance and deficiency of
either PD-1 or PD-L1 results in accelerated development of
diabetes in NOD mice (Wang et al., 2005; Keir et al., 2006).
The PD-1 pathway also functions to limit immune-mediated
damage. Tumors and chronic infections have exploited the
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PD-1 pathway to evade eradication by the immune system
(Greenwald et al., 2005; Freeman et al., 2006; Zou and
Chen, 2008).
PD-L2 is expressed mainly on activated DCs and macro-
phages (Ishida et al., 2002; Yamazaki et al., 2002; Liang
et al., 2003) whereas PD-L1 is broadly expressed on many
cell types. PD-L1 is upregulated after activation of B cells,
T cells, DCs, and macrophages (Ishida et al., 2002; Yamazaki
et al., 2002; Brown et al., 2003; Liang et al., 2003), and also
expressed on various parenchymal cells (Freeman et al.,
2000; Ansari et al., 2003; Brown et al., 2003; Iwai et al.,
2003; Liang et al., 2003; Salama et al., 2003; Wiendl
et al., 2003). Blockade of PD-1 ligands on human DCs
derived from monocytes enhances T-cell activation (Brown
et al., 2003).
Here we explore the expression of the immunoinhibitory
PD-1/PD-L pathway in human epidermal LCs. Our studies
show that PD-1 is expressed on immature (iLCs) in situ and
that this expression is functionally significant. PD-1 on iLCs
reduces IL-6 and macrophage inflammatory protein (MIP)-1a
cytokine production in response to Toll-like receptor-2 (TLR2)
signals. Expression of PD-1 declines on LCs with maturation,
whereas expression of PD-1 ligands increases. PD-L1 and
PD-L2 on migratory LCs (mLC) function to inhibit T-cell
responses.
RESULTS
Phenotypic differences between iLCs and mLCs
Our goal was to compare the phenotype and function of iLCs
and mLCs. As shown in Figure 1a, both iLCs and mLCs
expressed the typical LC markers CD1a and CD207
(Langerin). The maturation marker, CD83, was not expressed
on iLCs but was upregulated in mLCs (Figure 1b). The co-
stimulatory protein, CD80, was not expressed on iLCs but
strongly expressed on mLCs (Figure 1c). The co-stimulatory
protein, CD86, was weakly expressed on a subpopulation of
iLCs but strongly expressed on all mLCs (Figure 1d). These
results show clear changes in surface marker expression after
migration of LCs and suggest important differences in genetic
program and function between iLCs and mLCs.
PD-1 expression on human LCs
As expression of co-stimulatory proteins changes with LC
maturation, we examined the expression of co-inhibitory
receptors and ligands. Flow cytometric analysis showed that
the co-inhibitory receptor, PD-1, is present at moderate levels
on the cell surface of iLCs but expression is much lower on
mLCs (Figure 2a). To confirm this unexpected finding,
expression of PD-1 was examined by reverse transcrip-
tion–PCR (RT–PCR). Two preparations of iLCs expressed PD-1
mRNA as did the positive control of Jurkat cells transfected
with PD-1 cDNA, but expression was not detected on mLCs
or keratinocytes (Figure 2b). Localization of PD-1 on iLCs was
examined by immunofluorescence using confocal micro-
scopy. Both PD-1 and CD1a were primarily located on the
cell surface (Figure 2c). Immunohistochemical analysis of
serial sections of human skin showed expression of PD-1
together with CD207 on iLCs in the basal epidermis
(Figure 2d). Double staining of frozen sections of skin with
PD-1 and CD1a showed co-expression on LCs. These results
indicate that PD-1 is expressed on iLCs and declines with LC
migration due to decrease in gene expression.
PD-1 engagement on iLCs reduces TLR-mediated cytokine
production
In T cells, PD-1 engagement by PD-1 ligands diminishes
T-cell receptor (TCR)/CD28 signaling and PD-1 is described
as a co-inhibitory receptor. However, the role of PD-1
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Figure 1. Phenotypic differences between iLCs and mLCs. iLCs and mLCs
were prepared as described under Materials and Methods and phenotyped
using CD1a-FITC and the indicated PE-conjugated mAbs by flow cytometry:
CD207 (a); CD83 (b); CD80 (c);and CD86 (d). Similar results were seen in
three independent experiments.
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signaling in iLCs is unknown and it is unclear whether PD-1
in iLCs signals directly or modifies the signal from another
receptor. As TLR signals promote cytokine production by LCs,
we examined whether PD-1 engagement affected the levels
of TLR-induced LC cytokine production. We stimulated iLCs
with a TLR2 agonist, Pam3Cys (Niebuhr et al., 2009), as LCs
are known to express TLR2 (Peiser et al., 2008). To engage
PD-1 on iLCs, we cultured the iLCs with beads coated with
PD-L1-Ig, PD-L2-Ig, or an isotype IgG2a as control. We
examined the production of 11 cytokines that have been
reported to be produced by LCs after various treatments
(Wang et al., 1999). Pam3Cys induced the production of IL-6,
IL-10, MIP-1a, and MIP-1b. PD-1 engagement significantly
reduced Pam3Cys-induced production of IL-6 and MIP-1a in
three separate experiments (Figure 3c). PD-1 engagement
reduced the production of MIP-1b and IL-10, but this result
did not reach statistical significance (data not shown). Other
cytokines assayed, including IL-1a, IL-1b, tumor necrosis
factor-a, IL-12p40, IL-15, IL-18, and RANTES were expressed
at low/undetectable levels after treatment with Pam3Cys and
levels were not significantly affected by PD-1 engagement.
These results suggest that PD-1 can act as a co-inhibitory
receptor in iLCs, attenuating TLR-mediated signals.
PD-1 engagement on iLCs does not affect the expression of the
maturation markers CD83, CD80, and CD86
PD-1 engagement did not affect LC maturation, as judged by
a high percentage and mean fluorescence intensity of CD83,
CD80, and CD86 cell-surface maturation markers (Figure 3a
and b, and Table 1). In addition, TLR2 engagement by
Pam3Cys did not affect LC maturation and was not affected
by PD-1 engagement. These results suggest PD-1-mediated
co-inhibition is specific and not global.
PD-1 ligands are upregulated after migration of LCs
iLCs expressed low levels of PD-L1 and PD-L2; however,
mLCs expressed high levels of both PD-L1 and PD-L2
(Figure 4). Quantitation of mRNA expression levels in iLCs and
mLCs showed upregulation of PD-1 ligands in mLCs was due to
an increase in mRNA levels (Figure 4e and f). Unstimulated
keratinocytes did not express PD-L1 or PD-L2 mRNAs.
Blockade of the PD-1 pathway upregulates T-cell alloresponses
to mLCs
As LC maturation results in the upregulation of both co-
stimulatory (CD80, CD86) and co-inhibitory (PD-L1, PD-L2)
molecules, we examined the effects of blockade of the PD-1
pathway on a CD4 T-cell alloresponse to mLCs in 6 day and
in 40 hours cultures. Blockade of PD-L1 on mLCs signifi-
cantly augmented CD4 T-cell alloresponses (Figure 4g and h).
Blockade of PD-L2 significantly increased responses in the
40 hours culture, but the effect was not significant in the
6-day culture. Blockade of both together was more effective
than either alone. Blockade of PD-1 on T cells also
significantly augmented T-cell alloresponses. T cells or mLCs
alone did not proliferate significantly. These results indicate
that PD-L1 and PD-L2 on mLCs can engage PD-1 on T cells
and downregulate T-cell responses.
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Figure 2. PD-1 expression on LCs. (a) Purified iLCs and mLCs were
phenotyped by flow cytometry using the PD-1-PE mAb, gating on CD1a-
FITCþ cells. Jurkat cells transfected with PD-1 were included as positive
control. The results are representative of three independent experiments.
(b) RNA was prepared from the indicated cells and examined for PD-1 mRNA
expression by RT–PCR and gel electrophoresis of PCR products. (c) iLCs
were stained with CD1a-FITC and PD-1-PE and expression was localized
by confocal microscopy. (d) Sequential histological sections of normal
human skin were stained using PD-1 and CD207 mAbs. (e) A frozen section
of human skin was sequentially stained for PD-1 and CD1a as described
under Materials and Methods. 40-6-Diamidino-2-phenylindole was used to
visualize nuclei and the three images were merged to judge co-expression.
Bar¼20 mm (c–e).
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Blockade of the PD-1 pathway upregulates T-cell alloresponses
to DDCs and mLCs
We compared the effects of PD-1 pathway blockade on the
capacity of mLCs and dermal dendritic cells (DDCs) to
stimulate a T-cell alloresponse. DDCs were characterized as
CD11cþCD14 cells with low levels of CD1a (Figure 5a).
DDCs expressed high levels of PD-L1 and PD-L2 mRNA
(Figures 5b). Blockade of PD-L1 or PD-1 significantly
augmented CD4 T-cell alloresponses to both mLC and
DDC (Figure 5c and d). Blockade of PD-L2 alone did not
significantly increase alloresponses. Blockade of PD-L1 and
PD-L2 together was more effective than blockade of either
alone. These results show that PD-1 ligand expression is
significant in both populations of skin APCs.
DISCUSSION
Our work with human LCs shows constitutive expression of
PD-1 on iLCs in human skin. PD-1 expression has been
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Figure 3. PD-1 engagement reduces TLR2-induced cytokine production by iLCs but does not affect expression of CD83. iLCs were incubated with the
TLR2 agonist, Pam3Cys, and beads were coated with control IgG2a, PD-L1-Ig, or PD-L2-Ig. (a) After 24 hours, CD83 expression was evaluated by flow
cytometry; (b) the percentage and mean fluorescence intensity (MFI) of CD83 expression (mean±SD of three experiments) is shown. The open bars represent
cells treated with the indicated Ig fusion proteins and the filled bars represent cells treated with Ig fusion protein plus Pam3Cys. (c) Supernatants were harvested
at 24 hours and assayed for IL-6 and MIP-1a levels. Results from three experiments are shown with the statistical significance, P-values, shown on each graph.
Table 1. Expression of co-stimulatory cell-surface proteins by iLCs after 24 hours of PD-1 engagement and
stimulation with or without TLR2 agonist
IgG2a beads PD-L1-Ig beads PD-L2-Ig beads
+Pam3Cys Pam3Cys +Pam3Cys Pam3Cys +Pam3Cys Pam3Cys
% MFI % MFI % MFI % MFI % MFI % MFI
CD80 79.1 733 68.1 751 71.0 764 71.4 653 70.3 770 65.1 598
CD83 92.1 7,030 91.5 9,665 93.6 10,226 89.9 6,463 92.2 9,680 86.9 5,181
CD86 94.6 30,617 93.5 54,618 94.9 43,657 92.5 31,414 94.0 37,792 94.1 30,617
Abbreviations: iLC, immature Langerhans cell; LC, Langerhans cell; MFI, mean fluorescence intensity; PD-1, Programmed Death-1; PD-L1 and PD-L2, PD-1
ligands; TLR, Toll-like receptor.
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extensively studied in T cells and has recently been described
in stimulated murine DCs but has not been examined in LCs.
PD-1 expression can be induced on mouse splenic DC by
inflammatory stimuli, including Listeria monocytogenes
infection or TLR2, TLR3, TLR4, or NOD signaling (Yao
et al., 2009). PD-1-deficient DCs were more effective
than wild-type DCs in innate protection of mice against
L. monocytogenes lethal infection. PD-1 engagement on
PD-1þ splenic DCs downregulated IL-12 and tumor necrosis
factor-a production. These results show an emerging role for
PD-1 in the negative regulation of DC function during innate
immune responses. Our results with human LCs contrast with
the mouse DCs results in showing constitutive expression of
PD-1 in situ rather than induced expression, underscoring the
importance of our findings for immune responses in human
skin.
In T cells, engagement of PD-1 by PD-L1 or PD-L2 results
in phosphorylation of tyrosines in the PD-1 cytoplasmic
domain and recruitment of phosphatases, particularly SHP2
(Latchman et al., 2001; Chemnitz et al., 2004; Sheppard
et al., 2004), resulting in attenuation of the TCR signal. This
reduction in TCR signals also reduces the TCR-induced stop
signal, resulting in briefer engagement of the T cell with the
APCs (Fife et al., 2009). On the basis of this co-inhibitory
mechanism in T cells, we examined whether PD-1 engage-
ment could inhibit the the consequences of TLR2 signaling
in iLCs, as LCs express TLR2 and the TLR2 pathway is known
to involve tyrosine phosphorylation (Gray et al., 2006;
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Figure 4. PD-1 ligands are upregulated after migration of LCs and blockade of the PD-1 pathway upregulates CD4 T-cell alloresponses to mLCs. (a–d) iLCs and
mLCs were stained using PD-L1 or PD-L2 mAbs and analyzed by flow cytometry. RNA from iLCs, mLCs, and keratinocytes was analyzed for (e) PD-L1 and
(f) PD-L2 mRNA expression by qRT–PCR. (g, h) mLCs were incubated with 20 mg ml1 of the indicated mAb(s) for 1 hour and washed once. One group of CD4 T
cells was incubated with PD-1 mAb for 1 hour and washed once. 1102 mLCs and 1 105 previously activated allogeneic CD4 T cells were cultured together
and proliferation was measured by [3H]-thymidine incorporation for the last 16 hours of a (g) 6-day culture or (h) 40-hour culture. Statistical analysis was
performed using Student’s t-test. The experiments in panels a–d and g were repeated 3–5 times and the experiment in panel h was repeated once.
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Medvedev et al., 2007; MacLeod et al., 2008). We used a
TLR2 agonist, Pam3Cys (Niebuhr et al., 2009), to stimulate
iLCs in the presence or absence of PD-L1-Ig or PD-L2-Ig.
Pam3Cys induced the production of IL-6 and MIP-1a in iLCs;
furthermore, engagement of PD-1 reduced the production of
these cytokines. These results indicate that PD-1 in iLCs can
act in a co-inhibitory manner. PD-1 did not globally inhibit
LC maturation and had no effect on the expression of CD83,
CD80, or CD86.
Cytokine production by LCs may regulate tolerance and
immune responses. PD-1 engagement downregulated IL-6
and MIP-1a production by iLCs. IL-6 is a pleiotropic cytokine
known to be involved in inflammatory and autoimmune
diseases, and T-cell subset differentiation (Blanco et al.,
2008). MIP-1a is important for T-cell chemotaxis from the
circulation to inflamed tissue. These results suggest that PD-1
on iLCs can regulate LC function and suggest a wider analysis
of PD-1 function on LCs in vivo.
The cells that would naturally provide a PD-L1 or PD-L2
signal to PD-1 on iLCs remain to be determined. Previous
work has shown high levels of PD-L1 and PD-L2 on
keratinocytes during chronic inflammation (Freeman et al.,
2000; Youngnak-Piboonratanakit et al., 2004). IFN-g potently
upregulates PD-L1 expression on keratinocytes.
Here we show that as LCs migrate from the epidermis and
mature, expression of PD-1 declines and expression of PD-L1
and PD-L2 increases. This ‘‘reversal’’ of receptor/ligand
expression during cell maturation is also seen for some other
co-stimulatory pathways such as LIGHT/HVEM (Morel et al.,
2000; Tamada et al., 2000). As seen with other types of APCs,
we showed that blockade of either PD-L1 or PD-L2 on mLCs
enhanced T-cell activation. Dual blockade of PD-L1 and PD-
L2 led to the greatest increases indicating that both ligands
were active.
Maturation of LCs leads to high-level expression of major
histocompatibility complex class-II, co-stimulatory molecules
such as CD80, CD86, CD40, and CD83, as well as co-
inhibitory PD-L1 and PD-L2. This dual expression of co-
stimulatory and co-inhibitory molecules on APCs seems
paradoxical; however, T-cell populations differentially ex-
press receptors for co-stimulatory and co-inhibitory signals
and will respond differently. For instance, naı¨ve T cells
express CD28 but not cytotoxic T lymphocyte antigen-4 or
PD-1 (Greenwald et al., 2005), whereas ‘‘exhausted’’ CD8 T
cells or regulatory T cells express high levels of cytotoxic T
lymphocyte antigen-4 and PD-1 (Barber et al., 2006; Day
et al., 2006; Raimondi et al., 2006). Expression of both types
of ligand on an APC may permit fine-tuning of the T-cell
response and expression of the co-inhibitory ligands would
raise the threshold of TCR signal needed for T-cell activation.
This would reduce the response to weak antigens and focus
the response on antigens that deliver a strong TCR signal
(Latchman et al., 2001). Studies of the role of LCs in vivo
in mice show a role in the resolution of cutaneous immune
responses and inhibition of contact hypersensitivity and
responses against skin commensal microorganisms and
innocuous environmental antigens, and are reviewed
by Kaplan et al. (2008); Obhrai et al. (2008); and Igyarto
et al. (2009).
Consistent with previous studies showing that PD-1
engagement downregulates TCR or B-cell receptor signals
in lymphocytes, our results show that PD-1 engagement
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16 hours of a 6-day culture.
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can attenuate TLR signaling and downregulate cytokine
production in iLCs. Our experiments have identified one
function of PD-1 in LCs and further in vivo experiments are
needed to identify the complete function of PD-1 in LCs. On
the basis of our in vitro results, we speculate that PD-1
expression on iLCs in human skin could have a role in
reducing the APC functions of LCs before migration and
maintaining hyporesponsiveness in the steady state (Kaplan
et al., 2005; Obhrai et al., 2008; Vesely et al., 2009). The role
of PD-1 on APCs is just beginning to emerge and recent work
suggests that PD-1 on APCs has an important regulatory role.
MATERIALS AND METHODS
LC and DDC preparation
Normal human skin from reduction mammoplasties was acquired as
discarded material from Brigham and Women’s Hospital (Boston,
Massachusetts) after institutional IRB approval. LC extraction was
performed following our published method (Pena-Cruz et al., 2001).
After removing adipose tissue, skin was incubated in dispase grade-II
(Boehringer-Mannheim, Indianapolis, IN) overnight. The epidermis
was manually detached from the dermis. A single-cell suspension
was prepared by digestion with 2.5 mg ml1 trypsin (Sigma, St Louis,
MO) and 100 U ml1 DNase-I (Roche, Indianapolis, IN) in phos-
phate-buffered saline (PBS) at 37 1C for 30 minutes. Cells were
separated through an OptiPrep density gradient (Accurate Chemical
& Scientific Corp., Westbury, NY) (Pena-Cruz et al., 2001). iLCs
were enriched at 1.057 and 1.068 g ml1 densities, with purity of
75% as judged by CD1a expression, and viability was 495%. The
primary contaminating cells were keratinocytes. Purified keratino-
cytes were obtained from the 1.090-g ml1 density fraction. mLCs
and DDCs were obtained by incubating the epidermis or dermis,
respectively, for 48–72 hours in RPMI-1640 (Mediatech, Herndon,
VA) with 10% fetal bovine serum, 100 U ml1 penicillin, and
100mg ml1 streptomycin. Cells that had migrated out of the
epidermis were further purified by density gradient as above. mLCs
were enriched at 1.057 g ml1 and purity was 490% and viability
495%. DDCs were enriched at 1.057 g ml1 and purity was 490%
as judged by CD11c expression and viability 495%.
Confocal microscopy
iLCs were placed on 12-mm-diameter glass coverslips previously
treated with polylysine (Sigma, St Louis, MO). The attached cells
were fixed in 3.9% paraformaldehyde, permeabilized using 0.05%
saponin (Sigma, St Louis, MO), and stained using CD1a (OKT6-FITC)
and PD-1 (EH12-PE) for 1 hour (Diaz-Griffero et al., 2002).
Preparations were mounted using the Prolong Antifade kit (Invitro-
gen, Los Angeles, CA). Images were obtained using a Bio-Rad
Radiance 2000 laser-scanning confocal microscope with Nikon
 60 1.4 numerical aperture optics.
Immunohistochemistry
Human skin was fixed in formalin, paraffin-embedded, and
sectioned at 5mm thickness. For single-color immunohistochemistry,
deparaffinized sections were incubated with mAbs against CD207
(Immunotech, Marseille, France) or PD-1 (EH12) (Dorfman et al.,
2006), and then with biotinylated goat anti-mouse IgG followed by
treatment with streptavidin–peroxidase complex (Vector Labora-
tories, Burlingame, CA) and counter-stained with Giemsa. For
double staining, frozen sections were fixed with acetone and
methanol (1:1). After washing with PBS and incubation in 3%
BSA, tissue was incubated with PD-1 mAb (EH12) overnight at 4 1C.
After washing with PBS, sections were incubated with goat anti-
mouse IgG conjugated with Texas Red (Invitrogen, Eugene, OR) for
1 hour at room temperature, washed twice with PBS, and incubated
with CD1a (OKT6-FITC) for 2 hours at 4 1C. After washing, the slide
was mounted with Vectashield with 40-6-diamidino-2-phenylindole
(Vector Laboratories, Burlingame, CA). A Nikon Eclipse E800
microsope and a MetaVue imaging system were used for fluores-
cence microscopy (Molecular Devices, Madison, WI).
Flow cytometry
iLCs and mLCs were analyzed for cell-surface protein expression
using the following mAbs: CD1a, OKT6-FITC (Ortho-mune, Raritan,
NJ): Langerin, CD207-PE, and CD86-PE (Immunotech, Marseille,
France), CD80-PE, CD80-V450, CD83-PE, and CD86-APC (BD
Biosciences, San Diego, CA). mAbs against PD-1 (EH12, IgG1)
(Dorfman et al., 2006), PD-L1 (29E.2A3, IgG2b), and PD-L2
(24F.10C12, IgG2a) have been described by Brown et al. (2003).
MOPC31C (IgG1), MPC11 (IgG2b), and C1.18.4 (IgG2a) were used
as isotype controls (Bio-X-Cell, West Lebanon, NH). Phycoerythrin
(PE)-conjugated goat anti-mouse IgG1, IgG2a, and IgG2b were used
as secondary antibodies (Southern Biotech, Birmingham, AL). Flow
cytometry was performed using BD FACSCanto II and analyzed
using the BD FACSDiva software (Becton Dickinson, San Jose, CA);
and on a Cytomics FC500 (Beckman Coulter, Fullerton, CA) and
using the FlowJo software (Tree Star, Ashland, OR).
Cytokine assay
Cell culture supernatants were collected at 24 hours and assayed by
multiplex ELISA (Aushon Biosystems, Billerica, MA).
Preparation of coated beads and stimulation of LCs
Approximately 10 106 sulfate latex beads (5 mm diameter)
(Invitrogen, Eugene, OR) in 1 ml PBS were incubated with
10 mg ml1 PD-L1-Ig or PD-L2-Ig fusion protein (murine IgG2a Fc)
(Latchman et al., 2001), or the mIgG2a mAb, for 90 minutes at 371C.
The endotoxin levels of all proteins were less than 2 EU mg1. Fetal
bovine serum was then added to 1% and beads were washed. iLCs in
a round-bottomed, 96-well (1 105 but in one experiment,
1.7 105) were incubated with coated beads (5 105/well) in the
presence or absence of 400 ng ml1 of the TLR2 agonist, Pam3Cys
(EMC Microcollections, Tu¨bingen, Germany). Supernatants were
harvested after 24 hours and assayed for cytokine production.
RT–PCR
Total RNA was extracted from iLCs, mLCs, and human keratinocytes
using Trizol (Invitrogen, Carlsbad, CA). cDNA was prepared from
100 ng of total RNA according to the manufacturer’s protocol
(Applied Biosystems, Foster City, CA) and one-tenth of the reaction
mixture was used for PCR using Taqman reagents (Applied
Biosystems, Foster City, CA). PCR consisted of the following steps:
initiation at 95 1C for 10 minutes, then 40 cycles of 95 1C,
15 seconds, and 60 1C, 1 minute. The primer/probe sets for qRT–PCR
were from Applied Biosystems and were the following: PD-1
(PDCD1 Hs00169472_m1), PD-L1 (CD274 Hs00204257_m1), PD-
L2 (PDCD1LG2 Hs00228839_m1), and glyceraldehyde-3-phosphate
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dehydrogenase (GAPDH) (Hs99999905_m1). PCR was performed
using the Taqman Universal PCR Master Mix and the 7500 Real-
Time PCR System (Applied Biosystems, Foster City, CA) and relative
PD-L1 and PD-L2 expression was calculated using the formula 2DCT
(Kobayashi et al., 2007).
For semi-quantitative PCR, PCR products of PD-1 and GAPDH
were separated by electrophoresis on agarose gel (Cambrex,
Rockland, ME) and ethidium bromide-stained DNA bands were
photographed under UV light. Jurkat hPD-1, a cell line transfected
with human PD-1 cDNA, was used as a PD-1-positive control
(Latchman et al., 2001).
Mixed leukocyte reaction
Blood from human normal donors was obtained with DFCI IRB
approval and centrifuged on Ficoll–Hypaque. CD4 T cells were
purified by negative selection according to the manufacturer’s
protocol (Miltenyi Biotec, Auburn, CA). To induce PD-1 expression,
10 106 CD4 T cells were stimulated in media with 1mg ml1 CD28
mAb (37407; R&D Systems, Minneapolis, MN) in a 10 cm tissue
culture plate coated with 1mg ml1 CD3 mAb (OKT3; eBioscience,
San Diego, CA). T cells were harvested after 24 hours, washed, and
1 105 CD4 T cells were incubated with 1 102 allogeneic mLCs
per well, and proliferation measured by [3H]-thymidine incorpora-
tion (0.5 mCi well1; New England Nuclear, Boston, MA) for the last
16 hours of a 6-day culture. Where indicated, mLCs were incubated
with 20 mg ml1 PD-L1, PD-L2, or isotype control mAb(s) for 1 hour
and washed once before culture with T cells. One group of T cells
was incubated with PD-1 mAb for 1 hour and washed once before
culture with mLCs. Wells were done in quadruplicate.
Statistical analysis
Statistical analysis was performed using Excel (Microsoft, Redmond,
WA). Paired experimental groups were compared using a two-tailed
Student’s t-test.
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